William Wiesmann, M.D.
Chairman of the Board
Dr. William Wiesmann is Chairman of the Board of Synspira. Previously, he served as the Director for Combat Casualty Care at the U.S. Army Medical Research and Materiel Command Post, at Ft. Detrick, where he led the design and development teams that produced novel medical technologies. He is a member of the University of Cincinnati Department of Biomedical Engineering External Advisory Board and a member of the National Council at Washington University School of Medicine. He is a Trustee Emeritus at Harvey Mudd College in Claremont, California and recently served as an Ethan A.H. Shepley Trustee at Washington University. In 2008 he received an honorary doctorate of science from the University of Cincinnati recognizing his accomplishments in military and civilian trauma medicine. Dr. Wiesmann is a co-inventor of all Synspira technology.
Shenda Baker, Ph.D.
Chief Executive Officer
Dr. Shenda Baker is Chief Executive Officer of Synspira (interim). Dr. Baker has more than 25 years of experience in polymer chemistry and materials science and in leading, funding, and directing scientific research and development. She has extensive experience managing project execution, management of external consultants and advisors and business development efforts. She is President and COO of Synedgen Inc. Previously, she served as President of BioSTAR West, and as the lead scientific advisor to Hawaii Chitopure. She served on the Board of Directors of the Materials Research Society and has served on advisory boards with the National Institutes of Health, National Science Foundation and the Department of Energy. Dr. Baker is a member of the American Chemical Society and the Materials Research Society and currently serves on the Advisory Council of the National Institute of Dental and Craniofacial Research of the NIH. She is co-inventor on all Synspira technology.
Mr. Glenn Batchelder is Chairman of the Board for RESET Therapeutics and XyloCor Therapeutics. Mr. Batchelder was Co-Founder and CEO of Civitas Therapeutics, a development stage pulmonary delivery therapeutic company based on the ARCUS technology platform that was sold to Accorda Therapeutics. Prior to Civitas he also served as CEO of BIND Biosciences (sold to Pfizer), CEO of Acceleron Pharma (NASDAQ: XLRN) and SVP of Operations at Millennium Pharmaceuticals (sold to Takeda). During his more than 30 years of executive leadership experience he also served in functional roles including sales, marketing, business development, manufacturing, supply chain management and R&D. He also serves on the non-profit board of directors for the Michael J. Fox Foundation for Parkinson’s Research and The Possible Project. He is the former Chairman of the MassBio board.
Andrew W. Miller
Mr. Andrew W. Miller is President and CEO of Stimson Lumber Company in Portland, Oregon. Prior to joining Stimson in 1991, Mr. Miller was employed in the Forest Products Industry with Plum Creek Timber and Weyerhaeuser. He holds an undergraduate degree from Grinnell College and an MBA from Columbia University. Mr. Miller serves on multiple regional and national industry association Boards, and several non-profit Boards in the Portland area. He also serves on the Board of Directors at Synedgen.